|
시장보고서
상품코드
1654308
단위 용량 제조 시장 규모, 점유율, 동향 분석 보고서 : 조달 방법별, 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)Unit Dose Manufacturing Market Size, Share Trends Analysis Report By Sourcing (In-house, Outsourcing), By Product (Liquid, Solid), By End-use (Independent Pharmacies, Long Term Care), By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
단위 용량 제조 시장 성장과 동향:
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 단위 용량 제조 시장 규모는 2030년까지 1,506억 1,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 11.43%의 CAGR을 기록할 것으로 예상됩니다.
2020년 상반기에는 시장 성장이 정체되었지만, 2020년 말에는 회복세로 돌아섰습니다. 이는 주로 COVID-19 치료에 단위 용량이 사용되면서 동일한 병에서 용량을 취급하거나 주입할 때 위험이 감소했기 때문입니다.
단위 용량 제제는 약물을 쉽게 식별할 수 있고, 투약 시까지 약물의 제형을 보호할 수 있다는 많은 장점이 있습니다. 용기가 손상되지 않고 약물이 사용되지 않은 경우, 제제를 변경하지 않고 재처방 및 회수할 수 있습니다. 가장 중요한 장점은 적절한 양을 투여할 수 있고 환자가 규정된 한도를 초과하지 않도록 할 수 있다는 점입니다.
그러나 COVID-19 팬데믹은 의약품 시장에 큰 영향을 미치고 있으며, COVID-19 팬데믹의 전반기에 성장이 둔화되었지만 2020년 말부터 시장이 회복되기 시작했습니다. 단위 용량 제조는 취급 및 오염 위험을 줄이기 위해 현재 시나리오에서 유리하게 사용되고 있습니다. 또한, 단위 용량은 공기 감염이나 직접 접촉으로 인한 바이러스 감염 가능성을 배제하여 환자와 의료 종사자 모두를 보호하기 위해 COVID-19 환자를 위한 병원에서 널리 사용되고 있습니다.
단위 용량 제조 시장 보고서 하이라이트
- 조달 방식별로는 아웃소싱 부문이 2024년 매출 시장 점유율 60.74%로 가장 큰 비중을 차지하며 시장을 주도했습니다. 아웃소싱 서비스는 비용 효율성, 전문성, 유연성, 위험 감소, 세계 시장 접근성 등의 이유로 단위 용량 제조 산업을 지배했습니다.
- 고체 단위 용량 부문은 2024년 50.49%의 최대 매출 점유율로 시장을 주도했습니다. 정제 및 캡슐과 같은 고체 단위 용량 제형은 높은 수요, 광범위한 응용 분야 및 환자의 편의성으로 인해 단위 용량 마케팅을 지배하고 있습니다.
- 최종 용도별로는 독립 약국 부문이 2024년 39.11%의 최대 매출 점유율로 시장을 주도했으며, 예측 기간 동안 가장 빠른 CAGR을 기록할 것으로 예측됩니다.
- 북미는 2024년 37.73%의 가장 큰 매출 점유율로 단위 용량 제조 시장을 지배했습니다. 이 지역의 높은 의료 인프라, 만성질환의 높은 유병률, 환자 안전과 투약의 정확성에 초점을 맞춘 강력한 규제가 시장 수익의 성장을 주도하고 있습니다.
목차
제1장 분석 방법·범위
제2장 주요 요약
제3장 단위 용량 제조 시장 : 변수, 동향, 범위
- 시장 연관 전망
- 상부 시장 전망
- 관련/부수 시장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 기술 상황
- 가격 모델 분석
- 시장 분석 툴
- Porter's Five Forces 분석
- PESTEL 분석
- COVID-19의 영향 분석
제4장 단위 용량 제조 시장 : 조달 방법별 추정·동향 분석
- 부문 대시보드
- 단위 용량 제조 시장 : 조달 방법별 변동 분석
- 조달처별(2018-2030년)
- 사내
- 아웃소싱
제5장 단위 용량 제조 시장 : 제품별 추정·동향 분석
- 부문 대시보드
- 단위 용량 제조 시장 : 제품별 변동 분석
- 제품별(2018-2030년)
- 액체 단위 용량
- 고형 단위 용량
- 기타
제6장 단위 용량 제조 시장 : 최종 용도별 추정·동향 분석
- 부문 대시보드
- 단위 용량 제조 시장 : 최종 용도 변동 분석
- 최종 용도별(2018-2030년)
- 독립 약국
- 장기간병 시설
- 병원
- 기타
제7장 단위 용량 제조 시장 : 지역별 추정·동향 분석
- 시장 점유율 분석 : 지역별(2024년·2030년)
- 시장 대시보드 : 지역별
- 세계 시장 현황 : 지역별
- 북미
- 시장 추정과 예측,
- 미국
- 캐나다
- 멕시코
- 유럽
- 시장 추정과 예측,
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 스웨덴
- 덴마크
- 노르웨이
- 아시아태평양
- 시장 추정과 예측,
- 일본
- 중국
- 인도
- 태국
- 한국
- 호주
- 라틴아메리카
- 시장 추정과 예측,
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 시장 추정과 예측,
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 기업 분류
- 시장 리더
- 신흥 기업
- 기업 시장 상황 분석, 2024년(기업 히트맵 분석)
- 기업 개요
- Catalent Inc.
- Unither Pharmaceuticals
- Thermo Fisher Scientific
- Corden Pharma
- Mikart
- Tape Mark
- Renaissance Lakewood LLC
- Medical Packaging Inc
- American Health Packaging
- PCI Pharma Services
- Amcor PLC
- Bristol-Myers Squibb
- AbbVie Inc.
- Merck &Co. Inc.
- Pfizer Inc.
Unit Dose Manufacturing Market Growth & Trends:
The global unit dose manufacturing market size is expected to reach USD 150.61 billion by 2030, registering a CAGR of 11.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. In the first half of 2020, the growth of the market was stagnant, but the market started to recover by the end of 2020. It was mainly due to the use of unit doses for the treatment of COVID-19 as it decreases the risk involved while handling and pouring doses from the same bottle.
Unit dose manufacturing has many advantages as the drug can be easily identified, and the formulation of the drug is protected until the moment of administration. If the container is intact and the drug has not been used, it can be redisposed and retrieved without changing its formulation. The most important benefit is that it can be administered in the proper dosage and ensures that the patient does not exceed the prescribed limit.
However, the COVID-19 pandemic has a significant effect on the pharmaceutical market. The first half of the COVID-19 pandemic had slowed growth but by the end of 2020, the market started to recover. The unit dose manufacturing is lucratively used in the current scenario as it reduces the risk of handling and contamination. Also, unit doses are widely used in hospitals for COVID-19 patients to safeguard both patients and healthcare personnel to eliminate the possibility of viral transmission by airborne transmission or direct touch.
Unit Dose Manufacturing Market Report Highlights:
- By sourcing, the outsourcing segment led the market with the largest revenue market share of 60.74% in 2024. Outsourcing services dominated the unit dose manufacturing industry, owing to cost-effectiveness, expertise, flexibility, risk reduction, and access to global markets.
- The solid unit dose segment led the market with the largest revenue share of 50.49% in 2024. Solid unit dosage forms such as tablets and capsules dominate unit dose marketing due to their high demand, widespread applications, and patient convenience.
- Based on end use, the independent pharmacies segment led the market with the largest revenue share of 39.11% in 2024 and is also anticipated to register at the fastest CAGR over the forecast period.
- North America dominated the unit dose manufacturing market with the largest revenue share of 37.73% in 2024. The market revenue growth is driven by the region's advanced healthcare infrastructure, high prevalence of chronic diseases, and strong regulatory focus on patient safety and medication accuracy.
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates And Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Unit Dose Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increased Adoption of Unit Doses
- 3.2.1.2. Benefits of Manufacturing Unit Doses Over Repackaging
- 3.2.1.3. Growing Outsourcing Activities
- 3.2.1.4. Technological Advancements in Unit Dose Manufacturing
- 3.2.1.5. Increasing Prevalence of Chronic Diseases and Demand for Personalized Medicine
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Challenges Associated with the Adoption of Manufactured Unit Doses
- 3.2.2.2. Compliance Issues with Outsourcing
- 3.2.1. Market Driver Analysis
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. Market Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis
- 3.5.3. COVID-19 Impact Analysis
Chapter 4. Unit Dose Manufacturing Market: Sourcing Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Unit Dose Manufacturing Market: Sourcing Movement Analysis
- 4.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Sourcing, 2018 - 2030 (USD Million)
- 4.4. In-House
- 4.4.1. In-House Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 4.5. Outsourcing
- 4.5.1. Outsourcing Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Unit Dose Manufacturing Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Unit Dose Manufacturing Market: Product Movement Analysis
- 5.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
- 5.4. Liquid Unit Dose
- 5.4.1. Liquid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 5.5. Solid Unit Dose
- 5.5.1. Solid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Unit Dose Manufacturing Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Unit Dose Manufacturing Market: End Use Movement Analysis
- 6.3. Unit Dose Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
- 6.4. Independent Pharmacies
- 6.4.1. Independent Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.5. Long Term Care Facility
- 6.5.1. Long Term Care Facility Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.6. Hospitals
- 6.6.1. Hospitals Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Unit Dose Manufacturing Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. North America
- 7.4.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Thailand
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Australia
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
- 8.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
- 8.3. Company Profiles
- 8.3.1. Catalent Inc.
- 8.3.1.1. Company Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Service Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. Unither Pharmaceuticals
- 8.3.2.1. Company Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Service Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. Thermo Fisher Scientific
- 8.3.3.1. Company Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Service Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. Corden Pharma
- 8.3.4.1. Company Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Service Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. Mikart
- 8.3.5.1. Company Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Service Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Tape Mark
- 8.3.6.1. Company Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Service Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Renaissance Lakewood LLC
- 8.3.7.1. Company Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Service Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Medical Packaging Inc
- 8.3.8.1. Company Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Service Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. American Health Packaging
- 8.3.9.1. Company Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Service Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. PCI Pharma Services
- 8.3.10.1. Company Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Service Benchmarking
- 8.3.10.4. Strategic Initiatives
- 8.3.11. Amcor PLC
- 8.3.11.1. Company Overview
- 8.3.11.2. Financial Performance
- 8.3.11.3. Service Benchmarking
- 8.3.11.4. Strategic Initiatives
- 8.3.12. Bristol-Myers Squibb
- 8.3.12.1. Company Overview
- 8.3.12.2. Financial Performance
- 8.3.12.3. Service Benchmarking
- 8.3.12.4. Strategic Initiatives
- 8.3.13. AbbVie Inc.
- 8.3.13.1. Company Overview
- 8.3.13.2. Financial Performance
- 8.3.13.3. Service Benchmarking
- 8.3.13.4. Strategic Initiatives
- 8.3.14. Merck & Co. Inc.
- 8.3.14.1. Company Overview
- 8.3.14.2. Financial Performance
- 8.3.14.3. Service Benchmarking
- 8.3.14.4. Strategic Initiatives
- 8.3.15. Pfizer Inc.
- 8.3.15.1. Company Overview
- 8.3.15.2. Financial Performance
- 8.3.15.3. Service Benchmarking
- 8.3.15.4. Strategic Initiatives
- 8.3.1. Catalent Inc.
